KORU Medical Systems, Inc.

KORU Medical Systems reported a strong second quarter 2026, with net revenues increasing by 18.2% to $12.0 million and the company returning to a net profit of $0.25 million, or $0.01 EPS, compared to a net loss in the prior year. For the first six months, net revenues grew 20.1% to $23.8 million, and the net loss significantly narrowed. The company also amended its loan agreement, extending maturities and lowering the interest rate floor, and acquired intangible assets.

KORU Medical Systems reported strong second-quarter 2026 financial results, with net revenues growing 18.2% to $12.0 million and net income improving 222% to $0.25 million. The company also updated its full-year 2026 guidance, narrowing revenue expectations to $47.5 - $48.5 million and raising gross margin to 62% - 64%. Strategic highlights include the acquisition of a connected monitoring technology asset and a shift in its U.S. oncology market entry strategy, including withdrawing a 510(k) application.

KORU Medical Systems, Inc. amended its manufacturing and supply agreement with Command Medical Products, LLC, extending the initial term to December 31, 2031. The amendment includes modifications to pricing and payment terms, establishes Command as the exclusive manufacturer for certain products, and mandates Command to qualify a second manufacturing site by December 31, 2027, with KORU retaining termination rights for non-compliance. Additionally, the agreement clarifies intellectual property ownership and removes a non-competition provision.

KORU Medical Systems reported a 22.1% increase in net revenues to $11.8 million for the first quarter of 2026, with net loss narrowing by 30.8% to $0.8 million. The company saw strong growth across all segments, particularly in pharma services and clinical trials. Additionally, CEO Linda Tharby announced her retirement, transitioning to an advisory role, and the company amended its loan agreement to extend maturities and lower interest rates.

KORU Medical Systems reported first-quarter 2026 net revenues of $11.8 million, a 22% increase year-over-year, with gross profit growing 20% to $7.2 million. The company's net loss improved by 31% to ($0.8) million, or ($0.02) per diluted share. KORU Medical also reiterated its full-year 2026 guidance, expecting net revenues between $47.5 million and $50.0 million, and positive adjusted EBITDA and cash flow.

KORU Medical Systems amended its loan and security agreement with HSBC Ventures USA Inc., extending the Revolving Line Maturity Date to March 30, 2028, and the Term Loan Maturity Date to December 1, 2029. The amendment also introduces an EBITDA Milestone Event, which, if achieved by June 30, 2027, will extend the Draw Period End Date and Term Loan Amortization Date, providing KORU with more financial flexibility.

KORU Medical Systems amended its loan and security agreement with HSBC Ventures USA Inc., extending the Revolving Line Maturity Date to March 30, 2028, and the Term Loan Maturity Date to December 1, 2029. The amendment also modifies definitions related to the Draw Period, Term Loan Amortization Date, Adjusted EBITDA, and introduces the concept of Eligible Foreign Accounts, providing the company with more financial flexibility and potentially extending its access to capital.